Evaluation of Comparative Performance of Orally Inhaled Drug Products in View of the Classical Bioequivalence Paradigms: An Analysis of the Current Scientific and Regulatory Dilemmas of Inhaler Evaluation

被引：1
作者：
Everard, Mark [1 ]
机构：
[1] McCusker Fdn, Perth, WA, Australia
来源：
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY | 2014年 / 27卷 / 06期
关键词：
regulatory and regulations; Inhalation drug products; risk management; bioequivalence;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
O-1
引用
收藏
页码：A2 / A2
页数：1
相关论文
共 18 条
[1]  
Adams Wallace P, 2010, J Aerosol Med Pulm Drug Deliv, V23, P1, DOI 10.1089/jamp.2009.0803
[2]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[3]  
[Anonymous], IMM REL SOL OR DOS F
[4]   COMPARATIVE BIO-AVAILABILITY AND ACTIVITY OF PROPRIETARY TOPICAL CORTICOSTEROID PREPARATIONS - VASOCONSTRICTOR ASSAYS ON 31 OINTMENTS [J].
BARRY, BW ;
WOODFORD, R .
BRITISH JOURNAL OF DERMATOLOGY, 1975, 93 (05) :563-571
[5]   Equivalence Considerations for Orally Inhaled Products for Local Action-ISAM/IPAC-RS European Workshop Report [J].
Evans, Carole ;
Cipolla, David ;
Chesworth, Tim ;
Agurell, Eva ;
Ahrens, Richard ;
Conner, Dale ;
Dissanayake, Sanjeeva ;
Dolovich, Myrna ;
Doub, William ;
Fuglsang, Anders ;
Garcia Arieta, Afredo ;
Golden, Michael ;
Hermann, Robert ;
Hochhaus, Guenther ;
Holmes, Susan ;
Lafferty, Paul ;
Lyapustina, Svetlana ;
Nair, Parameswaran ;
O'Connor, Dennis ;
Parkins, David ;
Peterson, Ilse ;
Reisner, Colin ;
Sandell, Dennis ;
Singh, Gur Jai Pal ;
Weda, Marjolein ;
Watson, Patricia .
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2012, 25 (03) :117-139
[6]  
Guidance for Industry (Draft) US Food and Drug Administration, BIOEQ REC GEN FLUT P
[7]  
Guidance for Industry US Food and Drug Administration, 1999, SUPAC IR MR IMM REL
[8]  
Guidance for Industry US Food and Drug Administration, 1995, TOP DER CORT IN VIV
[9]  
Guidelines for Biopharmaceutical Studies in Man, 1972, GUID BIOPH STUD MAN, P6
[10]  
Kennedy EM, 1974, DRUG BIOEQUIVALENCE
12